Peregrine Pharmaceuticals | PPHM - Srodki Pieniężne I Ekwiwalent



Srodki Pieniężne I Ekwiwalent Zmiana Data
Agenus USD 3.46M 6.08M 2025-09
Amgen USD 9.13B 316M 2025-12
AstraZeneca USD 8.14B 1.08B 2025-09
BioCryst Pharmaceuticals USD 84.08M 3.95M 2025-09
Bristol-Myers Squibb USD 10.21B 5.52B 2025-12
Celldex Therapeutics USD 28.87M 7.17M 2025-12
Eli Lilly USD 7.27B 2.52B 2025-12
GlaxoSmithKline GBP 3.3B 303M 2025-09
Intrexon USD 9.34M 1.77M 2024-06
Karyopharm Therapeutics USD 37.67M 1.05M 2025-09
MacroGenics USD 80.13M 50.56M 2025-09
MannKind USD 74.88M 52.51M 2025-12
Merck USD 18.17B 10.16B 2025-09
Minerva Neurosciences USD 82.3M 70.02M 2025-12
Novartis USD 9.56B 2.9B 2025-09
Novavax USD 268.02M 14.28M 2025-09
Repligen USD 566.02M 182.73M 2025-12
Roche Holding CHF 7.55B 579M 2025-06
Xencor USD 54.07M 25.78M 2025-12